“A New Age: Update on Alzheimer’s Disease Diagnosis and Treatment,” by Lawrence Honig
Neurodegenerative dementia is increasingly prevalent due to our aging population. The most common disorder among these is Alzheimer’s disease (AD) which affect 7 million individuals in the US. There have been marked advances in diagnosis of AD, with noninvasive tests showing very high accuracy. And now we have FDA-approved medications that clearly slow disease progression. Currently neither very simple to use, now without risks, this situation nonetheless represents a sea-change for elderly persons with cognitive changes, and their physicians. We will review both new diagnostics and novel therapeutics currently available and in the pipeline—and their applicability and uses.
Dr. Lawrence Honig is a Professor of Neurology at Columbia University Irving Medical Center in New York City, and attending neurologist at New York Presbyterian Hospital and the New York State Psychiatric Institute. He is a neuroscientist and board-certified clinical neurologist, with UCNS subspecialty certifications in Behavioral Neurology and Neuropsychiatry, and Geriatric Neurology. His specialization focusses on aging and degenerative brain conditions including Alzheimer’s, Lewy Body, Frontotemporal, Progressive Supranuclear Palsy, and Creutzfeldt-Jakob diseases, and the immune-mediated encephalitides. His research activities focus on biomarkers in neurodegenerative disease, and include clinical drug trials, observational research, and translational investigations on molecular biomarkers of aging and dementia. He has authored more than 200 publications. He is also actively involved in clinical neurological care. He holds appointments in the Department of Neurology, the Gertrude H. Sergievsky Center, and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, at Columbia University Irving Medical Center, where he directs the New York State Center of Excellence for Alzheimer’s Disease (CEAD), and co-directs the Lewy Body Disease Association Research Center of Excellence (RCOE) and Progressive Supranuclear Palsy CurePSP Center of Care.
Register for Zoom link
